Abstract: Recent studies report that a single subtype of a1-adrenergic receptor (a1-AR), the a1A-subtype, mediates robust cardioprotective effects in multiple experimental models of heart failure, suggesting that the a1A-subtype is a potential therapeutic target for an agonist to treat heart failure. Moreover, we recently found that the a1A-subtype is present in human heart. The goal of this study was to assess the inotropic response mediated by the a1A-subtype in human myocardium, and to determine whether the response is downregulated in myocardium from failing human heart. We measured in vitro contractile responses of cardiac muscle preparations (trabeculae) isolated from the right ventricle from nonfailing and failing human hearts. Addition of the a1A-subtype agonist A61603 (100 nM) resulted in a large positive inotropic response (force increased z 2-fold). This response represented z70% of the response mediated by the b-adrenergic receptor agonist isoproterenol (1 mM). Moreover, in myocardium from failing hearts, a1A-subtype responses remained robust, and only slightly reduced relative to nonfailing hearts. We conclude that a1A-subtype-mediated inotropy could represent a significant source of inotropic support in the human heart. Furthermore, the a1A-subtype remains functional in myocardium from failing human hearts and thus, might be a therapeutic target to support cardioprotective effects in patients with heart failure.
INTRODUCTION
The myocardial contractile response to endogenous catecholamines is driven by cardiomyocyte beta-1 adrenergic receptors (b1-ARs) and alpha-1-ARs (a1-ARs). b1-adrenergic responses have been extensively studied and found to have consistent effects among studies. These effects include a robust positive inotropic effect (PIE).
By contrast, a1-AR responses have been less studied and show considerable variation among studies. 1 For example, there is marked species-dependent variation in the magnitude and direction of a1-AR inotropic responses, ranging from a robust PIE in rabbit and rat, to no response in dog. 2 Moreover, in studies of mice, a marked regional variation was found, with a PIE in left ventricular (LV) myocardium, but a negative inotropic effect (NIE) in right ventricular (RV) myocardium. 3 The presence of disease altered the a1-AR response; the NIE of nonfailing RV mouse myocardium was switched to a PIE in mouse models of RV failure induced by pulmonary fibrosis, 4 or secondary to LV failure after infarction. 5 Cardiac myocytes have 2 predominant a1-AR subtypes (a1A and a1B) and each subtype can mediate markedly different inotropic effects. For example, in rabbit, the a1A-subtype mediates an NIE, but the a1B-subtype mediates a PIE, 6 whereas in human, the a1A-subtype mediates a PIE, but the a1B-subtype mediates an NIE. 7 Recently, a1-ARs have gained new significance by the suggestion that a1-ARs can mediate powerful cardioprotective effects in heart failure. [8] [9] [10] Specifically, chronic stimulation of the a1A-subtype protects against cell death and improves function in mouse heart failure models based on doxorubicin toxicity, 11, 12 transaortic constriction, 13 or RV failure due to pulmonary fibrosis. 14 These findings raise the possibility that a1A-subtype signaling in humans might be a novel therapeutic target to treat heart failure.
The goal of this study was to assess the inotropic effect of a1A-subtype stimulation in human myocardium and determine how the inotropic effect is changed in human myocardium from failing hearts. We used the a1A-subtype-selective agonist A61603 that is highly potent and selective for the a1A-subtype. 12 We found a robust positive inotropic response to A61603 in myocardium from both nonfailing and failing human hearts. The a1A-subtype inotropic response represented z70% of the response elicited by stimulation of the b1-AR using isoproterenol.
We conclude that a1A-subtype-mediated inotropy could represent a significant source of inotropic support in the human heart. Furthermore, the a1A-subtype remains functional in myocardium from failing human hearts. As the a1A-subtype can mediate cardioprotective effects in animal heart failure models, the presence of a functional a1A-subtype in myocardium from failing human hearts suggests that the a1A-subtype might be a therapeutic target to support cardioprotective effects in patients with heart failure.
METHODS

Human Hearts
All human tissues were experimented on with approval from the institutional review board of The Ohio State University and conform to the Declaration of Helsinki. Informed consents were acquired from cardiac transplant patients. Explanted hearts from patients undergoing cardiac transplantation at The Ohio State University Wexner Medical Center were obtained directly in the operating room and immediately (within seconds) flushed with cardioplegic solution after removal from donors/patients as described previously. 15, 16 The hearts were transferred to the laboratory (within 10-30 minutes) in cold cardioplegic solution containing (in mM): 110 NaCl, 16 KCl, 16 MgCl 2 , 10 NaHCO 3 , and 0.5 CaCl 2 . All hearts were procured and treated with identical protocols, personnel, solutions, and timing regardless of the source. All end-stage failing hearts (n = 6) were acquired from patients in the operating room. Nontransplantable donor hearts (n = 6) were acquired in the operating room in collaboration with Lifeline of Ohio Organ Procurement. The biometric characteristics of these hearts are provided in Table 1 .
Trabecula Preparation
The right ventricle of the heart was transferred from the cardioplegic solution to a cold modified Krebs-Henseleit solution (K-H) bubbled with 95% O 2 -5% CO 2 containing (in mM): 137 NaCl, 5 KCl, 0.25 CaCl 2 , 20 NaHCO 3 , 1.2 NaH 2 PO 4 , 1.2 MgSO 4 , 10 dextrose, and 20 BDM (2,3-butanedione monoxime) and pH of 7.4. A linear, small, and free-running trabecula was isolated under a stereo dissection microscope, and kept in this solution at 0-48C until the time of the experiment, which was typically 2 hours or less. Approximately 10 trabeculae from each heart were harvested for use in separate parallel studies. One muscle per heart was used for this study. For both nonfailing and failing groups, data from 6 hearts were averaged per group. Muscles were transferred into custom-made setups as previously described for animal models 17 and the perfusion solution was changed to a modified K-H but without BDM. This solution was maintained at 378C and continuously bubbled with 95% O 2 -5% CO 2 , resulting in pH of 7.4. Continuous electrical stimulation was initiated (frequency of 0.5 Hz and stimulation voltage ;20% above threshold), and CaCl 2 concentration of the solution was slowly raised to 2 mM over ;15 minutes. Muscles were gradually stretched (over a few minutes) until an increase in developed force was exceeded by an increase in resting tension. This length (optimal length) roughly corresponds to sarcomere length of ;2.2 mm, which is near or at the in vivo sarcomere length at end-diastole. 18 Dimensions of the muscles from the nonfailing hearts used were 347 6 81 mm wide, 232 6 55 mm thick, and 2.7 6 0.7 mm long. Dimensions of the muscles from the failing hearts were not significantly different: 329 6 35 mm wide, 247 6 56 mm thick, and 2.4 6 0.5 mm long.
Inotropic Stimulation
After assessment of baseline contractility, we used supramaximal doses of both agonists. First, 100 nM of A61603 (Sigma) was added, and data were recorded when contractions had stabilized. Thereafter, the drug was washed out, and muscle contractile parameters returned back to baseline. Next, 1 mM isoproterenol was added, and data were again collected.
Statistical Analysis
Data are presented as mean 6 SE. Statistical tests (analysis of variance with post hoc analysis using Tukey correction for multiple comparisons, and paired and unpaired t tests) were performed using Prism 7 software (GraphPad Software, Inc, La Jolla, CA) with a significance level set at P , 0.05. RESULTS Figure 1 shows typical example records of the contractile responses to A61603 for a single muscle from a nonfailing heart (panel A), and for a single muscle from a failing heart (panel B). After washout of A61603, Figure 1 also shows the time course of the contractile response to isoproterenol (ISO) for these same muscles (in panels C and D, respectively).
For all muscles studied, the effects of A61603 and ISO on force development are summarized in Figure 2 . Shown are the individual experimental values (one muscle per heart) and the grouped data (mean 6 SE, n = 6 hearts per group). Baseline absolute contraction force (mN/mm 2 ) was similar in myocardium from nonfailing (16 6 3 mN/mm 2 ) versus failing hearts (15 6 3 mN/mm 2 ) (Fig. 2A) . Both A61603 and ISO elicited a robust PIE in nonfailing and failing myocardia. However, the inotropic responses showed considerable variability between subjects. After A61603 addition, there was a trend for greater absolute force level in nonfailing myocardium (39 6 9 mN/mm 2 ) versus failing myocardium (26 6 3 mN/mm 2 ), but this trend did not reach statistical significance (P = 0.21). Likewise, there was a trend for greater force level after ISO in nonfailing myocardium (51 6 7 mN/mm 2 ) versus failing (42 6 3 mN/mm 2 ) myocardium, which did not reach statistical significance (P = 0.27). Basal contractions and responses to ISO were similar to those observed in our recent studies 15, 16, 19, 20 .
To minimize intersubject variability, the contractile responses to A61603 and ISO were expressed relative to the baseline force before agonist (Fig. 2B ). After addition of A61603, force was increased z2-fold relative to the baseline force (Fig. 2B ) (2.4-fold for nonfailing vs. 1.9-fold for failing). After washout of A61603, after addition of isoproterenol, force was increased to a higher level (z3-fold relative to the baseline) (3.6-fold for nonfailing vs. 3.2-fold for failing). However, the higher level of force after ISO compared with after A61603 only reached statistical significance for the failing group, but not for the nonfailing group.
Isoproterenol is known to induce a high level of activation of contraction. Here, we compared the activation of contraction due to A61603 with that due to ISO (Fig. 2C) . The increase of force elicited by A61603 was z70% relative to the increase of force elicited by isoproterenol (74% for nonfailing vs. 63% for failing). There was no statistical difference between the nonfailing group and failing group. These data suggest that for both nonfailing and failing groups, the a1A-subtype is potentially a significant source of inotropic support. Figure 3 shows representative records of single electrically evoked contractions both before and after addition of agonists for 2 trabeculae, 1 from a nonfailing heart and 1 from a failing heart. For both nonfailing and failing heart, A61603 increased the contraction amplitude without affecting the time course of contraction or relaxation. By contrast, as expected, ISO increased the contraction amplitude and appreciably accelerated the timing of the phases of contraction and relaxation. Both agonists caused small reductions in diastolic force level. For nonfailing muscles, the drop of diastolic force after addition of A6 or ISO (1.4 6 0.4 and 0.9 6 0.3 mN/mm 2 , respectively) did not differ versus failing muscles (2.3 6 0.6 and 1.6 6 0.6 mN/mm 2 , respectively).
The contraction and relaxation phases were quantitated from the time between the start and peak of the contraction ( Fig. 4A) , and from the time from the peak of contraction to 50% relaxation (Fig. 4B) . Figure 4 shows that the pooled data for the contraction/relaxation timing parameters had less intersubject variability compared with the inotropic responses (Fig. 2) . The time to peak contraction (Fig. 4A) was not different between myocardium from nonfailing versus failing hearts. For each muscle, a change in timing parameters from before versus after agonist was evaluated using a paired t test. For both nonfailing and failing myocardia, the time to peak was not changed by addition of A61603 (P . 0.7, paired t test). However, the time to peak was significantly decreased FIGURE 2. Inotropic effects of A61603 and ISO on myocardium from nonfailing (NF) and failing (F) hearts. Individual experimental data (one muscle per heart) and pooled data (mean 6 SE, n = 6 hearts per group) for: (A) baseline forces and forces after addition of A61603 or ISO; (B) data for each muscle scaled relative to its predrug (baseline) contraction force; (C) responses to A61603 scaled relative to the response to ISO. *P , 0.05; **P , 0.01; and ***P , 0.001 for comparisons relative to baseline. †P , 0.05 and † †P , 0.01 for comparisons of ISO relative to A61603. FIGURE 3. Representative fast time-base recordings of twitch contractions. A, Electrically evoked twitch contraction records of trabecula from nonfailing heart at baseline (no drug) and after addition of 100 nM A61603. After washout of A61603,after addition of isoproterenol (P , 0.05, paired t test). The time to 50% relaxation (Fig. 4B ) was higher in myocardium from failing versus nonfailing hearts, indicating impaired relaxation. Relaxation time was not changed by addition of A61603 (P . 0.4, paired t test). After addition of isoproterenol, relaxation time was appreciably reduced (P , 0.05, paired t test), and there was no difference in relaxation time between nonfailing and failing groups.
DISCUSSION
We found that the a1A-subtype was functional in human myocardium from both nonfailing and failing hearts. The a1A-subtype produced a robust positive inotropic response representing about z70% of the response produced by the b1-AR. The a1A-subtype response was not appreciably downregulated in myocardium from failing hearts. These findings suggest that in the human heart, the a1A-subtype might represent a source of significant inotropic support.
Previous studies in experimental animals suggest that the a1A-subtype might be a novel therapeutic target to treat heart failure. In this context, we found that for human heart, the a1A-subtype remains functional in myocardium from failing hearts and thus might be a therapeutic target to treat patients with heart failure.
a1A-Subtype Inotropy in Human Myocardium
Previously, a1-AR-mediated inotropic responses involving increases of contraction in the range of 30%-60% were reported for rat and rabbit myocardia. [21] [22] [23] Similar a1-AR-mediated inotropic responses were reported for human myocardium. 22 For myocardium from failing rat hearts and from failing human hearts, the inotropic response to a1-AR stimulation was reported to be relatively increased compared with that evoked by b-AR stimulation. 22, 24 Moreover, human allografts explanted 10 years after transplantation showed a1-AR-mediated positive inotropic responses of similar size as native explanted hearts (z50-60%), demonstrating that a1-AR inotropic responses survived long-term immune-suppressant therapy. 25 Previously, we found that for myocardium dissected from cultured human cardiac tissue slices, the a1A-subtype elicited a PIE, whereas the a1B-subtype elicited an NIE. In the current study, using trabeculae from explanted hearts, we confirmed the presence of a PIE elicited by stimulation of the a1A-subtype. Moreover, we found that the inotropic response mediated by the a1A-subtype was appreciable, representing about z70% of the response produced by the b1-AR. We also found that a robust a1A-subtype inotropic response was present in myocardium from failing hearts.
The response to a1A-subtype stimulation did not involve a change in the timing of contraction or relaxation. This is consistent with the known lack of an effect of a1-AR stimulation on heart rate in vivo. By contrast, stimulation of b1-ARs markedly accelerated the timing of contraction and relaxation. Faster twitch kinetics are compatible with the known increase in heart rate that occurs during b1-AR stimulation in vivo.
Relation to Previous Studies
In studies of mouse myocardium, we previously reported that a1-AR stimulation elicits contrasting inotropic responses in LV versus RV myocardium. 3 Specifically, a1-AR agonist elicited a PIE in LV myocardium but an NIE in RV myocardium. Moreover, stimulation of the single a1A-subtype also resulted in contrasting responses, again with a PIE in LV, but an NIE in RV. 3 These responses in mouse differ from those observed in human. We recently reported that for human LV myocardium, a1A-subtype stimulation elicited a PIE. 7 In the current study, we found that for human RV myocardium, a1A-subtype stimulation also elicited a robust PIE. Thus, contrasting inotropic responses of LV versus RV myocardium after a1A-subtype stimulation were not observed in human.
For mouse RV myocardium, we found that the NIE of a1-AR stimulation was switched to a PIE in myocardium from failing hearts. 5 Moreover, we found that that this switch was due to the a1A-subtype that elicited an NIE in nonfailing RV myocardium but a PIE in RV myocardium from failing hearts. 4 For human myocardium, in this study, we did not observe appreciable difference in the a1A-subtype inotropic response in RV myocardium from nonfailing versus failing human hearts.
Collectively, these findings of different effects of a1A-subtype stimulation in mouse versus human suggest that caution is needed when extrapolating to human from studies using mice.
Previous studies suggest that the 3 cardiac a1-AR subtypes have different roles in cardiac inotropy. The a1A-AR subtype mediates a PIE in this study, consistent with previous studies. 4, 26 By contrast, the a1B-AR subtype generally mediates an NIE, 4, 27, 28 including in human myocardium. 7 The a1D-AR subtype mediates coronary vasoconstriction. 29 Thus, the inotropic response of human myocardium to nonsubtype-selective a1-AR agonist stimulation is likely complicated by both a PIE mediated by the a1A-AR subtype and an NIE mediated by the a1B-AR subtype.
a1A-Subtype Mediates Cardioprotective Effects
In studies of mouse models of heart failure, several lines of evidence suggest that the a1A-subtype can mediate powerful cardioprotective effects. Overexpression of the a1A-subtype increases contractility in vivo, 26 protects against pressure-overload-induced dysfunction, 30 and limits postinfarct cardiomyopathy. 31 Moreover, a1A-subtype stimulation protects cardiac myocytes against necrosis induced by oxidative stress, or toxicity from norepinephrine or doxorubicin. 32 Chronic administration of an a1A-subtype agonist protects against cardiomyopathy due to doxorubicin toxicity, 11,12 transaortic constriction, 13 or RV failure due to pulmonary fibrosis. 14 Notably, these chronic administration studies used a low dose of agonist that did not raise blood pressure through vascular a1-AR activation.
In human, a large clinical trial (ALLHAT) of an a1-AR antagonist was stopped prematurely because of an increase in heart failure in the a1-AR-antagonist-treated group. 33 This result suggests that a reduced level of a1-AR activation is injurious, and is consistent with a cardioprotective effect mediated by a1-ARs.
Together, these findings suggest the possibility that cardioprotective a1A-subtype signaling in humans might be a novel therapeutic target to treat heart failure. In view of this possibility, the current study suggests that the a1A-subtype is active in failing human myocardium.
Limitations
We studied RV endocardial trabeculae, which might have different inotropic properties compared with other RV regions and might also differ from LV myocardium. Moreover, for the patients with heart failure in this study, the extent of pathological involvement of the RV is unclear.
Some patients with heart failure were implanted with a Left Ventricular Assist Device (LVAD), which might lessen the extent of RV injury. However, there were no RV functional differences noted between heart failure patients with or without LVAD. Downregulation of b-ARs occurs in heart failure. However, the b-AR inotropic response was not reduced in myocardium from patients with heart failure. Nevertheless, the relaxation time was increased in the heart failure group, consistent with injury to RV myocardium.
The agonist ISO was always evaluated after A61603. In pilot studies, we found that the effects of ISO took a long time to wash out and were not completely reversed. A long washout time would result in considerable time-dependent loss of function (run down) that occurs due to progressive impairment of excitation-contraction coupling. 19 Therefore, in this study, ISO was used after A61603. We used a single maximal dose of each agonist. Our recent study found that A61603 is highly potent in both nonfailing and failing human myocardium with an EC50 of 5 nM for activation of cell signaling that is well below the 100 nM dose used in the current study. 7 
CONCLUSIONS
The a1A-subtype mediates a robust PIE in human myocardium. Thus, a1A-subtype-mediated inotropy could represent a significant source of inotropic support in the human heart. Furthermore, the a1A-subtype remains functional in myocardium from failing human hearts. As the a1A-subtype mediates cardioprotective effects in animal heart failure models, the presence of a functional a1A-subtype in myocardium from failing human hearts suggests that the a1A-subtype might be a therapeutic target to treat patients with heart failure.
